Long-term assessment of haematological recovery following somatic genetic rescue in a MYSM1-deficient patient: Implications for in vivo gene therapy

Br J Haematol. 2024 Dec;205(6):2349-2354. doi: 10.1111/bjh.19744. Epub 2024 Sep 4.

Abstract

MYSM1 deficiency causes inherited bone marrow failure syndrome (IBMFS). We have previously identified an IBMFS patient with a homozygous pathogenic variant in MYSM1 who recovered from cytopenia due to spontaneous correction of one MYSM1 variant in the haematopoietic compartment, an event called somatic genetic rescue (SGR). The study of the genetic and biological aspects of the patient's haematopoietic/lymphopoietic system over a decade after SGR shows that one genetically corrected haematopoietic stem cell (HSC) can restore a healthy and stable haematopoietic system. This supports in vivo gene correction of HSCs as a promising treatment for IBMFS, including MYSM1 deficiency.

Keywords: MYSM1; bone marrow failure; haematopoiesis; natural gene therapy; somatic genetic rescue.

Publication types

  • Case Reports

MeSH terms

  • Bone Marrow Failure Disorders / genetics
  • Bone Marrow Failure Disorders / therapy
  • Female
  • Genetic Therapy* / methods
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Male